Directors Share Purchase and Options Grant

Quantum Pharma Plc

("Quantum" or the "Company")

Directors Share Purchase and Options Grant

Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, received notifications on 10 March 2016 that Andrew Scaife, Chief Executive Officer of the Company, purchased 37,000 ordinary shares of 10 pence each in the Company ("Ordinary Shares") at a price of 68 pence per share and Chris Rigg, Chief Financial Officer of the Company, purchased 15,000 Ordinary Shares at a price of 66 pence per share.

Additionally, Quantum announces that on 10 March 2016, it granted options over 500,000 Ordinary Shares at an exercise price of 100 pence in accordance with the rules of the Quantum Long Term Incentive Plan 2014. An option over 250,000 Ordinary Shares has been granted to Chris Rigg and an option over 250,000 Ordinary Shares has been granted to a member of the senior management team. In each case the award is related to the commencement of their employment with the Company. Subject to the satisfaction of the required performance criteria, this grant will vest upon publication of the results of the Company for the year ending 31 January 2018.

Following these transactions:

· Andrew Scaife has an interest in 3,342,303 Ordinary Shares representing 2.673% of the total issued share capital and an option over 1,501,500 Ordinary Shares.

· Chris Rigg has an interest in 15,000 Ordinary Shares representing 0.012% of the total issued share capital and an option over 250,000 Ordinary Shares.

- Ends -

For further information:

Media enquiries:

Notes to Editors

Quantum Pharma is a service-led, niche pharmaceutical manufacturer, developer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

Specials

Comprising four business units:

Quantum Pharmaceutical manufactures and supplies specials and special obtains for pharmacy chains, pharmaceutical wholesalers, hospitals and independent pharmacies in the UK.

UL Medicines sources and supplies unlicensed imported medicines, batch-made and bespoke specials to hospitals, community pharmacies and wholesalers in the UK and overseas.

NuPharm offers outsourced manufacture for solid and liquid dose batch-made specials and niche licensed medicines, product development as well as clinical trials product manufacture.

Quantum Aseptic Services manufactures aseptically prepared, sterile intravenous products, either individually, for named patients or in batches for supply to private and NHS hospitals and homecare patients.

Niche Pharmaceuticals

Comprising three business units:

Colonis® is a product development business, which takes niche pharmaceutical products through the regulatory pathway to achieve licensed and/or regulated status.

Lamda is a full-service contract development specialist with customers across Europe. It specialises in creating added-value products with distinct advantages for patients and health care providers. It also provides full services for the entire development chain - from inception to registration to post-approval, finished product supply and regulatory support.

PERN Consumer Products, owner of the Dermacool brand - a range of menthol in aqueous creams.

Medication Adherence

Comprising two business units:

Biodose® is a medicines delivery system that accommodates liquid and solid medication, supporting medicines administration and adherence, for patients, their carers and clinicians. Biodose Connect® - a telehealth version with the ability to remotely monitor medication adherence is in live testing.

Biodose Services® assembles and delivers pre-prepared medication regimes to care homes and homecare patients, incorporating Biodose® as appropriate.

For further information, please visit www.quantumpharmagroup.com.